Abstract Library

#4667 Clinical outcomes in patients with typical (TC) and atypical bronchial carcinoids (AC): A 15-year retrospective study from an ENETS Center of Excellence

Introduction: Bronchial neuroendocrine neoplasms (NENs) can be subdivided into TCs, ACs and neuroendocrine carcinomas (NECs). Although a few studies have explored treatment approaches and oncological outcomes, most focus on surgical cohorts, small sample sizes, or mixed groups including TC, AC, and NECs. Real-life cohort data are lacking.

Conference:

Presenting Author: Clement D

Authors: Correia J, Sarker D, Dolly S, Frydman A, Srirajaskanthan R,

Keywords: bronchial carcinoid, treatment pattern, recurrence-free survival, overall survival,

#4666 Merkel cell neuroendocrine carcinoma of the skin: High response rates to short course palliative radiotherapy – Typical clinical scenarios

Introduction: Merkel cell carcinomas (MCC) are a rare, aggressive skin neuroendocrine carcinomas, with peak incidence in the elderly. MCC often presents as a firm, red/purple painless nodule with a short history of increasing size. Surgery is considered the 1st line treatment but elderly patients, in particular, have comorbidities which may preclude radical surgery requiring reconstruction. In advanced MCC, immunotherapy (IO) is 1st line systemic treatment. Chemotherapy is used 2nd line or if contraindications for IO but can be challenging in an elderly population. There may be an emerging role for PRRT due to the presence of somatostatin receptors on MCC. Radiotherapy (RT) can be used for non-surgical candidates, or those with unresectable or metastatic disease. Adjuvant post-operative irradiation (PORT) may provide additional benefit in risk reduction and improves local control.

Conference:

Presenting Author:

Authors: Saunders E, Sizer B, Collins J, Skelly R, Srinivasan G,

Keywords: Merkel cell, skin, radiotherapy,

#4648 Analysis of presentation and outcomes of mixed adenoneuroendocrine carcinoma (MANEC) – A single centre experience

Introduction: Mixed adenoneuroendocrine carcinoma (MANEC) is a rare neoplasm characterised by the coexistence of both adenocarcinoma and neuroendocrine carcinoma components. Due to its rarity, limited data exist regarding its clinical presentation, treatment strategies, and outcomes. This study provides an analysis of MANEC cases from a single centre, providing insights into its clinical features, diagnostic challenges, treatment strategies, and prognosis.

Conference:

Presenting Author: Khosla D

Authors: Khosla D, Kapoor R, Mehta A, Gupta R, Singh H,

Keywords: MANEC, mixed adenoneuroendocrine carcinoma, treatment,

#4628 Triple negative breast neuroendocrine carcinoma in older patient: A rare entity

Introduction: Neuroendocrine breast carcinoma is a rare histological form of breast cancer, that represent 0.1% of all breast cancers and is recognised by the World Health Organization as a distinct entity. Characterised by a non-specific clinical and radiological presentation. Therapeutic management is not codified and is usually superimposed on that of classical breast cancer.

Conference:

Presenting Author:

Authors: Aris H, Saidi M, Lahfa I,

Keywords: neuroendocrine carcinoma, triple negative breast cancer, platinum-based combination therapy,

#4605 Primary mammary neuroendocrine tumour: A case report and literature review

Introduction: Primary neuroendocrine carcinomas of the breast are rare, accounting for only 2 to 5% of all breast cancers. These tumours have recently been included in the latest WHO classification of breast tumours. The diagnosis can be challenging due to its uncommon presentation and overlap with other breast pathologies.

Conference:

Presenting Author:

Authors: Boudersa A, Kouadri N,

Keywords: primary neuroendocrine, breast cancer,